The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, as detected by an FDA-approved test. The FDA also approved VENTANA PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody, from Ventana Medical Systems, Roche Diagnostics (RHHBY), as a companion diagnostic device to aid in identifying patients with BTC who may be eligible for treatment with Ziihera.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
- Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera
- Jazz Pharmaceuticals announces FDA approval of Ziihera in BTC
- Jazz Pharmaceuticals price target raised to $162 from $154 at Baird
- Biotech Alert: Searches spiking for these stocks today